Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
stocks
10 best US blue-chip shares to buy for the long term
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,570.90 | 30.80 | -0.36% |
CAC 40 | 8,154.51 | 31.93 | 0.39% |
DAX 40 | 22,287.56 | 27.09 | -0.12% |
Dow JONES (US) | 43,428.02 | 748.63 | -1.69% |
FTSE 100 | 8,659.37 | 3.60 | -0.04% |
HKSE | 23,477.92 | 900.94 | 3.99% |
NASDAQ | 19,524.01 | 438.36 | -2.20% |
Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
S&P 500 | 6,013.13 | 104.39 | -1.71% |
S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
SSE Composite Index | 3,379.11 | 28.33 | 0.85% |